Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT06066424 |
TitlePhase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | 阶段
第 1 阶段
|
Date Added 2023-10-04 |
地点
Texas, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
招聘
|
药物
Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06065371 |
TitleSacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy | 阶段
第 1 阶段
|
Date Added 2023-10-03 |
地点
Michigan, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
capecitabine, Sacituzumab govetican |
标签
MSS/ MMRp
|
| NCT ID NCT06060704 |
TitleEnvafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | 阶段
第二阶段
|
Date Added 2023-09-29 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Bevacizumab, Envafolimab, Trifluridine/Tipiracil, Avastin, Lonsurf |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06055439 |
Title评估自体钙粘蛋白 17 嵌合抗原受体 (CAR) T 细胞疗法 CHM-2101 的 1/2 期研究 | 阶段
Phase 1, Phase 2
|
Date Added 2023-09-26 |
地点
Georgia, United States
Illinois, United States Pennsylvania, United States Tennessee, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06047015 |
TitleIrreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer | 阶段
第 1 阶段
|
Date Added 2023-09-21 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSS/ MMRp
|
| NCT ID NCT06043713 |
Title表达高亲和性 KRASG12V 突变特异性 T 细胞受体的自体 CD8+ 和 CD4+ 转基因 T 细胞（FH-A11KRASG12V-TCR）用于治疗 KRAS G12V 突变的转移性胰腺癌、结直肠癌和非小细胞肺癌患者 | 阶段
第 1 阶段
|
Date Added 2023-09-21 |
地点
Washington, United States
|
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
Bendamustine, Cyclophosphamide, Fludarabine |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06039202 |
TitleCA102N 联合 TAS-102 与贝伐珠单抗联合 TAS-102 治疗复发性和/或难治性转移性结直肠癌受试者的 2 期研究比较 | 阶段
第二阶段
|
Date Added 2023-09-15 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
CA102N, TAS-102 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06039384 |
TitleINCB099280 联合 Adagrasib 治疗携带 KRASG12C 突变的晚期实体瘤成人研究 | 阶段
第 1 阶段
|
Date Added 2023-09-15 |
地点
California, United States
Colorado, United States Michigan, United States Texas, United States Virginia, United States 意大利 西班牙 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Adagrasib, INCB099280 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06034860 |
TitleStudy of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types | 阶段
第 1 阶段
|
Date Added 2023-09-13 |
地点
California, United States
Indiana, United States Missouri, United States New York, United States Virginia, United States |
Prior IO Allowed 是 |
CRC-directed 没有 |
Status
活跃，非招募
|
药物
MT-8421, Nivolumab, Opdivo |
标签
MSI-H/ MMRd
|
| NCT ID NCT06026774 |
TitleClinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms | 阶段
第 1 阶段
|
Date Added 2023-09-07 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
